PHARMACEUTICAL COMPANY EXAMPLE
OUR MISSION
To develop and bring to market safe, effective pain medications that will replace opioids as the standard of care for pain management.ABOUT CMXTWENTY
Cmxtwenty is a Milwaukee-based pharmaceutical company focused on development of a non-narcotic treatment for pain using a unique lipid molecule called CMX-020. This molecule is an analog of arachidonic acid with a multi-modal mechanism of action, including CB1, CB2, Melatonin MT1, Adenosine A3, kappa- and delta-opioid, and TRPV1 receptors. Unlike opioid pain therapeutics, CMX-020 does not activate the mu-opioid receptor that produces devastating effects. CMX-020’s physiochemical properties are similar to the active metabolite of acetaminophen (AM404). Like acetaminophen, CMX-020 reduces pain without feeling the effects of the drug itself. The lack of “drug feel” associated with CMX-020 mitigates side effect complications and the risk of addiction to the patient. CMX-020 can be delivered intravenously in a hospital setting and orally. Cmxtwenty maintains international patent filings on CMX-020 through 2029 (excluding extensions).
CMX-020 can be delivered intravenously in a hospital setting and orally
WHY DOES THIS MATTER?
The Problem: Opioid Crisis
The opioid crisis in the United States is killing approximately 22,000 people in hospitals and 50,000 people from overdose every year, with an additional two million Americans addicted to prescription or illicit opioids.
The President declared a National Health Emergency on October 26, 2017, saying effective immediately, “I am directing all executive agencies to use every appropriate emergency authority to fight the opioid crisis.”
The Answer: CMX-020
We have developed both intravenous and oral drug candidates with safety and efficacy profiles powerful enough to replace opioids as the standard of care for severe pain relief. The impact of our discoveries on global healthcare could be as important as the discovery of penicillin.